Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug

Alvogen Group Inc.'s Norwich unit won’t be allowed to sell its proposed copies of Xofluza for as long as 14 years under an agreement to end a patent suit over the flu drug brought by Roche Holding AG units and Shionogi & Co.

Norwich Pharmaceuticals Inc. is blocked from selling its 40- and 80-milligram generic tablets of baloxavir marboxil, Xofluza’s active ingredient, until the earlier of a confidential entry date or the October 2039 expiration of the latest asserted patent, absent a court ruling that the patents are invalid or unenforceable, according to Judge Maryellen Noreika’s order issued Wednesday in ...